pharmaphorum

MARCH 23, 2021

The big Swiss pharma added this drug to its pipeline after it swooped for Endocyte and so far it looks like a good piece of business, with potential blockbuster sales predicted for the drug if it makes it to market. Novartis’ radioligand therapy Lu-PSMA-617 has met its target in prostate cancer, as its $2.1

Trials 124

Trials Hormones Sales Drugs 124

Pharmaceutical Technology

MAY 25, 2023

Mellozzan contains the sleep hormone melatonin and is indicated for use in children with attention deficit hyperactivity disorder (ADHD) and sleep difficulties. The deal includes licence income for specified individual key markets along with profit sharing on future Mellozzan sales.

Hormones 130

Hormones Engineer Containment Licensing 130

XTalks

MARCH 18, 2025

Standard treatment strategies include combinations of antibiotics, hormonal therapies and biologic agents most notably adalimumab (Humira), the only FDA-approved biologic for moderate to severe cases while surgery remains an option for advanced disease.

Trials 59

Trials Clinical Trials Clinical Trials Hormones 59

pharmaphorum

FEBRUARY 21, 2022

It’s a key moment for the two companies, as expansion into HER2-low breast cancer has been held up as a key requirement for Enhertu (trastuzumab deruxtecan) if it is to achieve its multibillion-dollar sales expectations. billion to Daiichi Sankyo if all the ADC’s development and sales objectives are achieved.

Trials 132

Trials Sales Hormones Drugs 132

Pharmaceutical Technology

NOVEMBER 30, 2022

We’re using a combination of gut hormones to mimic the effectiveness of bariatric surgery. Over the past few years, there has been a boom in anti-obesity drug development, with major companies achieving substantial sales in the field. Mounjaro is a combination of the two gut hormones GLP-1 and GIP. million in Q3.

Drugs 264

Drugs Manufacturing Hormones Clinical Trials 264

XTalks

JANUARY 29, 2025

Related: Eli Lillys Zepbound Approved as First Treatment for Obstructive Sleep Apnea The commercial describes Zepbounds mechanism of action as a dual receptor against that works by activating two naturally occurring hormone receptors in [the] body [GLP-1 and GIP-1]. Late last year, Zepbound brought in $1.26

FDA Approval 71

FDA Approval Drugs Hormones Marketing 71

pharmaphorum

AUGUST 15, 2022

At this year’s ASCO congress, the Trop2-targeting antibody-drug conjugate (ADC) was found to improve progression-free survival significantly in in patients with hormone receptor-positive, HER2-negative metastatic breast cancer who received multiple lines of prior treatment.

HR 90

HR Hormones Sales Antibody 90

pharmaphorum

DECEMBER 3, 2021

When this happens, the first line of drug treatment if the tumours are hormone-sensitive is ADT, with chemotherapy layered on top if needed. Around 95% of prostate cancers are localised at diagnosis and treated with surgery or radiotherapy, but tend to relapse.

Trials 107

Trials Sales Hormones Drugs 107

Pharmaceutical Technology

NOVEMBER 30, 2022

We’re using a combination of gut hormones to mimic the effectiveness of bariatric surgery. Over the past few years, there has been a boom in anti-obesity drug development, with major companies achieving substantial sales in the field. Mounjaro is a combination of the two gut hormones GLP-1 and GIP. million in Q3.

Drugs 246

Drugs Manufacturing Hormones Clinical Trials 246

Pharmaceutical Technology

JUNE 6, 2023

Ecubectedin is a small molecule commercialized by Pharma Mar, with a leading Phase II program in Hormone Sensitive Breast Cancer. Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV).

Hormones 100

Hormones In-Vitro Genotype Bacteria 100

pharmaphorum

AUGUST 11, 2020

A phase 3 trial is expected to begin in 2021 and the company says that the compound could generate peak sales of more than a billion euros globally. At the beginning of this year, KaNDy completed a phase 2b trial of its first-in-class drug NT-814, showing activity against symptoms of the menopause such as hot flashes and night sweats.

Drugs 98

Drugs Hormones Marketing Trials 98

Pharmaceutical Technology

APRIL 19, 2023

In 2012, Bayer entered a five-year, multi-target collaboration with Evotec which yielded six non-hormonal pre-clinical candidates, two of which advanced to Phase I development: BAY2328065 and BAY2395840.

Gene Therapy 130

Gene Therapy Hormones Production Sales 130

Pharmaceutical Technology

JUNE 5, 2023

Rezvilutamide is indicated for the treatment of metastatic hormone sensitive prostate cancer. The company offers products through its sales and distribution network in China, the US, Japan, Germany Switzerland, and Australia. Rezvilutamide overview Rezvilutamide is an antineoplastic agent.

Medicine 100

Medicine Hormones Production Clinical Trials 100

Pharmaceutical Technology

JUNE 5, 2023

Rezvilutamide is indicated for the treatment of metastatic hormone sensitive prostate cancer. The company offers products through its sales and distribution network in China, the US, Japan, Germany Switzerland, and Australia. Rezvilutamide overview Rezvilutamide is an antineoplastic agent.

Medicine 100

Medicine Hormones Production Clinical Trials 100

Pharmaceutical Technology

SEPTEMBER 8, 2022

The information contained within the download document is intended for pharmacists, pharmaceutical executives, sales managers, manufacturers, business development managers, pharmaceutical sales representatives, and any other individual involved in the pharmaceutical compounding sector. . • Test method development.

Marketing 100

Marketing Pharmacy Containment Sales 100

pharmaphorum

MARCH 8, 2021

The cost-effectiveness agency is assessing use of Lynparza (olaparib) in patients with tumours that carry BRCA1 or BRCA2 mutations who have previously been treated with the hormone therapies abiraterone and enzalutamide but have relapsed.

Hormones 98

Hormones Marketing Trials DNA 98

XTalks

NOVEMBER 3, 2022

Mounjaro has thus taken off stronger than expected, surpassing Wall Street sales forecasts during the third quarter. Mounjaro was approved this summer as a Type 2 diabetes treatment and is the first diabetes drug with dual action, targeting two hormones involved in insulin production and appetite (GIP and GLP-1).

Sales 98

Sales FDA Approval Production Insulin 98

pharmaphorum

APRIL 25, 2022

The Swiss pharma said in its update that the acelERA trial comparing giredestrant to physician’s choice of endocrine therapy for previously-treated hormone receptor (HR)-positive, HER2-negative breast cancer did not meet its primary endpoint of improving progression-free survival (PFS). Ocrevus rose 18% to CHF 1.4

Trials 69

Trials Hormones HR Sales 69

XTalks

JULY 19, 2024

The meteoric rise in the popularity of GLP-1 medications has created a breeding ground for online scams and the sale of unauthorized products,” said LegitScript CEO Scott Roth in a press release.

Pharmacy 104

Pharmacy Drugs Production Sales 104

pharmaphorum

OCTOBER 11, 2020

Pfizer already makes big revenues from its breast cancer drug Ibrance, but a late-stage trial failure has set back its hopes of even loftier sales – and set up a challenge from Eli Lilly’s rival drug Verzenio.

Trials 52

Trials HR Hormones Drugs 52

XTalks

JANUARY 23, 2024

Pediatric growth hormone deficiency (PGHD) is one such condition, affecting a child’s growth and development. This rare endocrine disorder, characterized by inadequate secretion of growth hormone from the pituitary gland, has profound impacts on physical and sometimes cognitive development.

Development 72

Development Hormones Drugs Trials 72

The Pharma Data

AUGUST 11, 2020

After this, the agreement promises further “triple digit million” milestone payments to be made once sales goals are hit. It has been projected that, if successful, the drug could rake in as much as €1 billion in global sales at its peak. The deal is expected to close by September this year. Matt Fellows. Source link.

Hormones 52

Hormones Sales Medicine Development 52

Pharmaceutical Technology

FEBRUARY 18, 2023

Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Hormones 100

Hormones Development Production Clinical Trials 100

pharmaphorum

OCTOBER 24, 2022

for Myovant – which develops hormonal therapies for conditions like uterine fibroids, endometriosis and prostate cancer – but that was deemed inadequate and was turned down earlier this month. Sales of the two products were $4 million and $36 million respectively in Myovant’s fiscal first quarter ended 30 June 2022.

Production 75

Production Hormones Marketing Sales 75

pharmaphorum

SEPTEMBER 22, 2022

The company said this morning that US sales growth is its main priority, and that it will be led in the near-term by “high-value” new drugs Kisqali (ribociclib), iptacopan, Pluvicto (lutetium Lu 177 vipivotide tetraxetan), remibrutinib, and Scemblix (asciminib).

Sales 52

Sales Trials Hormones Clinical Trials 52

Pharmaceutical Technology

FEBRUARY 28, 2023

Cushing’s syndrome is caused by an excess of the hormone cortisol in the body, leading to symptoms such as depression and excess fat on the chest or stomach. Furthermore, Argentina’s total pharmaceutical sales is expected to grow by 44.2 This disease affects approximately 13 individuals per million annually.

Marketing 130

Marketing Drugs Production Sales 130

pharmaphorum

OCTOBER 14, 2022

The EU decision follows a green light from the FDA for longer-duration use of Mirena – an intrauterine device (IUD) that also delivers the hormone levonorgestrel – in August. Approximately 17% of women of reproductive age (around 160 million worldwide) use intrauterine contraception, including hormone-releasing products.

Hormones 59

Hormones Compliance Clinical Trials Clinical Trials 59

pharmaphorum

SEPTEMBER 14, 2020

The partnership will see the companies pursuing a joint development programme testing ladiratuzumab vedotin as monotherapy and in combination with Merck anti-PD-1 therapy Keytruda (pembrolizumab) in triple-negative breast cancer, hormone receptor-positive breast cancer, and other LIV-1 expressing solid tumours. billion equity investment in 5.0

Genetics 52

Genetics Development Drugs Protein 52

pharmaphorum

SEPTEMBER 24, 2021

The results of the PROpel study showed that a combination of Lynparza (olaparib) and Johnson & Johnson’s hormonal therapy Zytiga (abiraterone acetate) given as a first-line treatment to an -all-comer’ population of men with metastatic castration-resistant prostate cancer (mCRPC) delayed disease progression.

Hormones 52

Hormones Genetics Drugs Sales 52

pharmaphorum

JULY 29, 2021

Advanz hiked the price of a pack of liothyronine tablets – used to treat thyroid hormone deficiency – from £20 in 2009 to £248 in 2017, taking advantage of a lack of competition for the drug even though it was out of patent.

Drugs 98

Drugs Marketing Generic Drugs Hormones 98

pharmaphorum

SEPTEMBER 21, 2022

Takeda is also in line for just over $287 million in potential milestone payments, plus royalties on net sales if it reaches the market. Enter Puma Biotech, which is paying a modest $7 million upfront for rights to alisertib (formerly MLN8237) and plans to run clinical trials of the compound in breast and lung cancers.

Drugs 64

Drugs HR Licensing Licensing 64

pharmaphorum

MAY 6, 2022

For Pluvicto that includes a pair of phase 3 trials in metastatic hormone-sensitive prostate cancer and metastatic castration-resistant prostate cancer, while for Lutathera it will affect studies for brain cancer glioblastoma, extensive-stage small cell lung cancer, and new NET indications.

Manufacturing 52

Manufacturing Hormones Clinical Trials Clinical Trials 52

pharmaphorum

JULY 13, 2022

“Targeting CYP11A1 provides a compelling approach to suppressing the production of steroid hormones,” said Dean Li, president of Merck Research Laboratories. It is rumoured to be near to announcing a $40 billion takeover bid for the biotech.

Licensing 52

Licensing Licensing Hormones Production 52

The Pharma Data

MARCH 31, 2022

The company’s Supply Center in Berlin will be transformed into a Center of Excellence for parenterals, and the Supply Center in Leverkusen into a Center of Excellence for non-hormonal solids. The Supply Center Bergkamen will become a Center of Excellence for contrast media and hormone products while expanding capacities for therapeutics.

Production 52

Production Manufacturing Hormones Gene Therapy 52

pharmaphorum

OCTOBER 12, 2022

Gilead Sciences will hear back from the FDA in February next year about its marketing application for Trodelvy in hormone receptor-positive, HER2-negative metastatic breast cancer, billed by the drugmaker as a key new indication for the drug.

HR 52

HR Sales Antibody Hormones 52

XTalks

MARCH 15, 2023

Norepinephrine is a hormone and neurotransmitter that helps in alertness and maintaining control in high-stress situations. In 2022, global sales of the drug totalled $115.3 Since its 2021 approval, Qelbree made a significant leap in sales last year due to its expanded approval in adults, having gone from $9.9 million in 2022.

Drugs 98

Drugs Sales Trials Marketing 98

pharmaphorum

SEPTEMBER 9, 2022

Prospects for Gilead Sciences’ Trodelvy in hormone receptor-positive, HER2-negative metastatic breast cancer continue to improve as data from the TROPiCs-02 trial strengthen, but the jury is still out on what that might mean for the drug commercially.

HR 52

HR Hormones Trials Sales 52